Kenfarb & Co’s Novartis NVS Stock Holding History

Kenfarb & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$428K	Hold	4,200	–	–	0.39%	68
2023 Q2	$424K	Hold	4,200	–	–	0.37%	71
2023 Q1	$386K	Hold	4,200	–	–	0.35%	74
2022 Q4	$381K	Hold	4,200	–	–	0.34%	69
2022 Q3	$319K	Hold	4,200	–	–	0.3%	75
2022 Q2	$369K	Hold	4,200	–	–	0.29%	80
2022 Q1	$369K	Hold	4,200	–	–	0.29%	80
2021 Q4	$367K	Buy	+4,200	New	+$349K	0.27%	79

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kenfarb & Co's NVS Position: Q3 2023 in Review

Kenfarb & Co held its Novartis (NVS) position steady in Q3 2023 at 4,200 shares worth $428K. The position accounts for 0.39% of the portfolio, ranked #68.

Kenfarb & Co first reported a position in NVS in Q4 2021 and has held it in 8 quarters since. 1,223 funds tracked by Wall St. Rank hold NVS as of Q3 2023.

Kenfarb & Co held 4,200 shares of Novartis worth $428K as of Q3 2023.
Kenfarb & Co left its Novartis share count unchanged in Q3 2023.
Novartis made up 0.39% of Kenfarb & Co's portfolio in Q3 2023, its #68 holding.
Kenfarb & Co first reported a position in Novartis in Q4 2021 and has held it in 8 quarters since.
1,223 funds tracked by Wall St. Rank held Novartis as of Q3 2023.

Based on Kenfarb & Co's 13F filing for Q3 2023, filed 14 Nov 2023.